Novavax, Inc. (NVAX) Dividend History

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19. In June 2013, Novavax acquired the Matrix-M adjuvant platform with the purchase of Swedish company Isconova AB and renamed its new subsidiary Novavax AB.

Last update 08/06/2022


Dividend Yield Summary

  2017 2018 2019 2020 2021 2022
Dividends - - - - - -
Average Price 1.17 1.76 3.74 69.30 193.65 69.22
Yield - - - - - -
• The above Dividend, Average Price, and Yield values for 2022 are year-to-date.

Dividend History

No history of dividends
Date Amount Per Share Note